227 related articles for article (PubMed ID: 23518928)
21. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.
Catalano S; Marsico S; Giordano C; Mauro L; Rizza P; Panno ML; Andò S
J Biol Chem; 2003 Aug; 278(31):28668-76. PubMed ID: 12734209
[TBL] [Abstract][Full Text] [Related]
22. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
23. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L
Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888
[TBL] [Abstract][Full Text] [Related]
24. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Wang L; Ellsworth KA; Moon I; Pelleymounter LL; Eckloff BW; Martin YN; Fridley BL; Jenkins GD; Batzler A; Suman VJ; Ravi S; Dixon JM; Miller WR; Wieben ED; Buzdar A; Weinshilboum RM; Ingle JN
Cancer Res; 2010 Jan; 70(1):319-28. PubMed ID: 20048079
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Johansson H; Aristarco V; Gandini S; Gjerde J; Macis D; Guerrieri-Gonzaga A; Serrano D; Lazzeroni M; Rajasekaran A; Williard CV; Mellgren G; DeCensi A; Bonanni B
Pharmacogenomics J; 2020 Feb; 20(1):19-26. PubMed ID: 30967597
[TBL] [Abstract][Full Text] [Related]
26. TSPYL5 suppresses p53 levels and function by physical interaction with USP7.
Epping MT; Meijer LA; Krijgsman O; Bos JL; Pandolfi PP; Bernards R
Nat Cell Biol; 2011 Jan; 13(1):102-8. PubMed ID: 21170034
[TBL] [Abstract][Full Text] [Related]
27. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
28. Serum Estradiol and 20 Site-Specific Cancers in Women: Mendelian Randomization Study.
Larsson SC; Kar S; Perry JRB; Carter P; Vithayathil M; Mason AM; Easton DF; Burgess S
J Clin Endocrinol Metab; 2022 Jan; 107(2):e467-e474. PubMed ID: 34601599
[TBL] [Abstract][Full Text] [Related]
29. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Prosperi JR; Robertson FM
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):55-70. PubMed ID: 16997132
[TBL] [Abstract][Full Text] [Related]
31. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Dudenkov TM; Liu D; Cairns J; Devarajan S; Zhuang Y; Ingle JN; Buzdar AU; Robson ME; Kubo M; Batzler A; Barman P; Jenkins GD; Carlson EE; Goetz MP; Northfelt DW; Moreno-Aspitia A; Desta Z; Reid JM; Kalari KR; Wang L; Weinshilboum RM
Clin Pharmacol Ther; 2019 Jul; 106(1):219-227. PubMed ID: 30648747
[TBL] [Abstract][Full Text] [Related]
32. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor alpha and nuclear factor Y coordinately regulate the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast cancer cells.
Ying S; Dünnebier T; Si J; Hamann U
PLoS One; 2013; 8(9):e75695. PubMed ID: 24086615
[TBL] [Abstract][Full Text] [Related]
34. The transcription factor SMAD4 and miR-10b contribute to E2 release and cell apoptosis in ovarian granulosa cells by targeting CYP19A1.
Li Q; Du X; Pan Z; Zhang L; Li Q
Mol Cell Endocrinol; 2018 Nov; 476():84-95. PubMed ID: 29723543
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin promotes aromatase expression and estradiol production in human adipocytes.
Leitner L; Jürets A; Itariu BK; Keck M; Prager G; Langer F; Grablowitz V; Zeyda M; Stulnig TM
Breast Cancer Res Treat; 2015 Nov; 154(1):63-9. PubMed ID: 26482249
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Ramaswamy B; Majumder S; Roy S; Ghoshal K; Kutay H; Datta J; Younes M; Shapiro CL; Motiwala T; Jacob ST
Mol Endocrinol; 2009 Feb; 23(2):176-87. PubMed ID: 19095770
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor alpha (ERalpha) mediates stimulatory effects of estrogen on aromatase (CYP19) gene expression in human placenta.
Kumar P; Kamat A; Mendelson CR
Mol Endocrinol; 2009 Jun; 23(6):784-93. PubMed ID: 19299445
[TBL] [Abstract][Full Text] [Related]
39. Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men.
Eriksson AL; Perry JRB; Coviello AD; Delgado GE; Ferrucci L; Hoffman AR; Huhtaniemi IT; Ikram MA; Karlsson MK; Kleber ME; Laughlin GA; Liu Y; Lorentzon M; Lunetta KL; Mellström D; Murabito JM; Murray A; Nethander M; Nielson CM; Prokopenko I; Pye SR; Raffel LJ; Rivadeneira F; Srikanth P; Stolk L; Teumer A; Travison TG; Uitterlinden AG; Vaidya D; Vanderschueren D; Zmuda JM; März W; Orwoll ES; Ouyang P; Vandenput L; Wu FCW; de Jong FH; Bhasin S; Kiel DP; Ohlsson C
J Clin Endocrinol Metab; 2018 Mar; 103(3):991-1004. PubMed ID: 29325096
[TBL] [Abstract][Full Text] [Related]
40. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
